Cord blood transplantation is associated with good outcomes in secondary Acute Myeloid Leukemia in first remission

Frédéric Baron, Myriam Labopin, Annalisa Ruggeri, Fernanda Volt, Mohamad Mohty, Didier Blaise, Patrice Chevallier, Jaime Sanz, Nathalie Fegueux, Jan J Cornelissen, Alessandro Rambaldi, Bipin Savani, Eliane Gluckman, Arnon Nagler

Research output: Contribution to journalArticle

Abstract

BACKGROUND: We conducted a retrospective survey within the European Society for Blood and Marrow Transplantation (EBMT) registry to assess the outcomes of cord blood transplantation (CBT) in secondary acute myeloid leukemia (sAML).

METHODS: Inclusion criteria consisted of ≥ 18 years of age, sAML, first CBT between 2002 and 2016, and either first complete remission (CR) or active disease at CBT.

RESULTS: One hundred forty six patients met the study inclusion criteria. Status at transplantation was first CR (n=97), primary refractory sAML (n=30) or relapsed (n=19) sAML. Neutrophil engraftment was achieved in 118 patients while the remaining 25 patients (17%) failed to engraft. This include 13% of patients transplanted in first CR versus 30% of those transplanted with active disease (P=0.008)). Two-year incidences of relapse were 25% in first CR patients versus 36% in those with advanced disease (P=0.06) while 2-year incidences of nonrelapse mortality were 35% and 49% (P=0.03), respectively. At 2-year overall survival, leukemia-free survival and graft-versus-host disease (GVHD)-free relapse free survival were 42% versus 19% (P<0.001), 40% versus 16% (P<0.001), and 26% versus 12% (P=0.002) in first CR patients versus those with advanced disease, respectively.

CONCLUSIONS: We report here the first study of CBT in a large cohort of sAML patients. Main observation was that CBT rescued approximately 40% of patients with sAML in first CR. This article is protected by copyright. All rights reserved.

Original languageEnglish
JournalJournal of Internal Medicine
DOIs
Publication statusE-pub ahead of print - Dec 18 2018
Externally publishedYes

Fingerprint

Fetal Blood
Acute Myeloid Leukemia
Transplantation
Survival
Recurrence
Incidence
Graft vs Host Disease
Registries
Leukemia
Neutrophils
Bone Marrow
Observation
Mortality

Cite this

Cord blood transplantation is associated with good outcomes in secondary Acute Myeloid Leukemia in first remission. / Baron, Frédéric; Labopin, Myriam; Ruggeri, Annalisa; Volt, Fernanda; Mohty, Mohamad; Blaise, Didier; Chevallier, Patrice; Sanz, Jaime; Fegueux, Nathalie; Cornelissen, Jan J; Rambaldi, Alessandro; Savani, Bipin; Gluckman, Eliane; Nagler, Arnon.

In: Journal of Internal Medicine, 18.12.2018.

Research output: Contribution to journalArticle

Baron, F, Labopin, M, Ruggeri, A, Volt, F, Mohty, M, Blaise, D, Chevallier, P, Sanz, J, Fegueux, N, Cornelissen, JJ, Rambaldi, A, Savani, B, Gluckman, E & Nagler, A 2018, 'Cord blood transplantation is associated with good outcomes in secondary Acute Myeloid Leukemia in first remission', Journal of Internal Medicine. https://doi.org/10.1111/joim.12870
Baron, Frédéric ; Labopin, Myriam ; Ruggeri, Annalisa ; Volt, Fernanda ; Mohty, Mohamad ; Blaise, Didier ; Chevallier, Patrice ; Sanz, Jaime ; Fegueux, Nathalie ; Cornelissen, Jan J ; Rambaldi, Alessandro ; Savani, Bipin ; Gluckman, Eliane ; Nagler, Arnon. / Cord blood transplantation is associated with good outcomes in secondary Acute Myeloid Leukemia in first remission. In: Journal of Internal Medicine. 2018.
@article{4795f265921b44cd86da41a0e495b2ab,
title = "Cord blood transplantation is associated with good outcomes in secondary Acute Myeloid Leukemia in first remission",
abstract = "BACKGROUND: We conducted a retrospective survey within the European Society for Blood and Marrow Transplantation (EBMT) registry to assess the outcomes of cord blood transplantation (CBT) in secondary acute myeloid leukemia (sAML).METHODS: Inclusion criteria consisted of ≥ 18 years of age, sAML, first CBT between 2002 and 2016, and either first complete remission (CR) or active disease at CBT.RESULTS: One hundred forty six patients met the study inclusion criteria. Status at transplantation was first CR (n=97), primary refractory sAML (n=30) or relapsed (n=19) sAML. Neutrophil engraftment was achieved in 118 patients while the remaining 25 patients (17{\%}) failed to engraft. This include 13{\%} of patients transplanted in first CR versus 30{\%} of those transplanted with active disease (P=0.008)). Two-year incidences of relapse were 25{\%} in first CR patients versus 36{\%} in those with advanced disease (P=0.06) while 2-year incidences of nonrelapse mortality were 35{\%} and 49{\%} (P=0.03), respectively. At 2-year overall survival, leukemia-free survival and graft-versus-host disease (GVHD)-free relapse free survival were 42{\%} versus 19{\%} (P<0.001), 40{\%} versus 16{\%} (P<0.001), and 26{\%} versus 12{\%} (P=0.002) in first CR patients versus those with advanced disease, respectively.CONCLUSIONS: We report here the first study of CBT in a large cohort of sAML patients. Main observation was that CBT rescued approximately 40{\%} of patients with sAML in first CR. This article is protected by copyright. All rights reserved.",
author = "Fr{\'e}d{\'e}ric Baron and Myriam Labopin and Annalisa Ruggeri and Fernanda Volt and Mohamad Mohty and Didier Blaise and Patrice Chevallier and Jaime Sanz and Nathalie Fegueux and Cornelissen, {Jan J} and Alessandro Rambaldi and Bipin Savani and Eliane Gluckman and Arnon Nagler",
note = "This article is protected by copyright. All rights reserved.",
year = "2018",
month = "12",
day = "18",
doi = "10.1111/joim.12870",
language = "English",
journal = "Journal of Internal Medicine",
issn = "0954-6820",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Cord blood transplantation is associated with good outcomes in secondary Acute Myeloid Leukemia in first remission

AU - Baron, Frédéric

AU - Labopin, Myriam

AU - Ruggeri, Annalisa

AU - Volt, Fernanda

AU - Mohty, Mohamad

AU - Blaise, Didier

AU - Chevallier, Patrice

AU - Sanz, Jaime

AU - Fegueux, Nathalie

AU - Cornelissen, Jan J

AU - Rambaldi, Alessandro

AU - Savani, Bipin

AU - Gluckman, Eliane

AU - Nagler, Arnon

N1 - This article is protected by copyright. All rights reserved.

PY - 2018/12/18

Y1 - 2018/12/18

N2 - BACKGROUND: We conducted a retrospective survey within the European Society for Blood and Marrow Transplantation (EBMT) registry to assess the outcomes of cord blood transplantation (CBT) in secondary acute myeloid leukemia (sAML).METHODS: Inclusion criteria consisted of ≥ 18 years of age, sAML, first CBT between 2002 and 2016, and either first complete remission (CR) or active disease at CBT.RESULTS: One hundred forty six patients met the study inclusion criteria. Status at transplantation was first CR (n=97), primary refractory sAML (n=30) or relapsed (n=19) sAML. Neutrophil engraftment was achieved in 118 patients while the remaining 25 patients (17%) failed to engraft. This include 13% of patients transplanted in first CR versus 30% of those transplanted with active disease (P=0.008)). Two-year incidences of relapse were 25% in first CR patients versus 36% in those with advanced disease (P=0.06) while 2-year incidences of nonrelapse mortality were 35% and 49% (P=0.03), respectively. At 2-year overall survival, leukemia-free survival and graft-versus-host disease (GVHD)-free relapse free survival were 42% versus 19% (P<0.001), 40% versus 16% (P<0.001), and 26% versus 12% (P=0.002) in first CR patients versus those with advanced disease, respectively.CONCLUSIONS: We report here the first study of CBT in a large cohort of sAML patients. Main observation was that CBT rescued approximately 40% of patients with sAML in first CR. This article is protected by copyright. All rights reserved.

AB - BACKGROUND: We conducted a retrospective survey within the European Society for Blood and Marrow Transplantation (EBMT) registry to assess the outcomes of cord blood transplantation (CBT) in secondary acute myeloid leukemia (sAML).METHODS: Inclusion criteria consisted of ≥ 18 years of age, sAML, first CBT between 2002 and 2016, and either first complete remission (CR) or active disease at CBT.RESULTS: One hundred forty six patients met the study inclusion criteria. Status at transplantation was first CR (n=97), primary refractory sAML (n=30) or relapsed (n=19) sAML. Neutrophil engraftment was achieved in 118 patients while the remaining 25 patients (17%) failed to engraft. This include 13% of patients transplanted in first CR versus 30% of those transplanted with active disease (P=0.008)). Two-year incidences of relapse were 25% in first CR patients versus 36% in those with advanced disease (P=0.06) while 2-year incidences of nonrelapse mortality were 35% and 49% (P=0.03), respectively. At 2-year overall survival, leukemia-free survival and graft-versus-host disease (GVHD)-free relapse free survival were 42% versus 19% (P<0.001), 40% versus 16% (P<0.001), and 26% versus 12% (P=0.002) in first CR patients versus those with advanced disease, respectively.CONCLUSIONS: We report here the first study of CBT in a large cohort of sAML patients. Main observation was that CBT rescued approximately 40% of patients with sAML in first CR. This article is protected by copyright. All rights reserved.

U2 - 10.1111/joim.12870

DO - 10.1111/joim.12870

M3 - Article

C2 - 30561052

JO - Journal of Internal Medicine

JF - Journal of Internal Medicine

SN - 0954-6820

ER -